EUVIMEDEUVIMED entdecken
Fallbericht

Lenalidomide Treatment of Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy

Qing Zhang, Yi Dong, Zhimin Zhai, Lili Tao, Qianshan Tao

Acta Haematologica · 2024

DOI: 10.1159/000537719 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Acta Haematologica, 2024. Verfasst von Qing Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, stuqingzhang@126.com. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Lenalidomide, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T (CAR-T) cell are effective treatments for acute lymphoblastic leukemia (ALL). Various forms of intra- and extramedullary relapses have been reported after HSCT and CAR-T-cell therapy for ALL; however, no reports have investigated isolated central nervous system (CNS) relapse after HSCT and CAR-T-cell therapy. Hence, no clinical treatment has been established for such rare patients. Case Presentation: An 18-year-old male patient with B-cell ALL suffered from isolated CNS relapse after HSCT and CAR-T-cell therapy. Conventional systemic intravenous and intrathecal chemotherapies were ineffective and intolerable. A unique immunosuppressive microenvironment of decreasing NK cell percentage and increasing IL-8 concentration and CAR-T-cell exhaustion had been illustrated in the cerebrospinal fluid. Finally, the patient received immunomodulatory therapy with lenalidomide and obtained complete remission.

Conclusion

Lenalidomide might be a therapeutic strategy for isolated CNS relapse after HSCT and CAR-T-cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLenalidomidePrecursor Cell Lymphoblastic Leukemia-LymphomaImmunotherapy, AdoptiveHumansMaleAdolescentReceptors, Chimeric AntigenCentral Nervous System NeoplasmsRecurrence

Stichwörter der Autor:innen

Acute lymphoblastic leukemiaCentral nervous system leukemiaChimeric antigen receptor T cellHematopoietic stem cell transplantationLenalidomide

Substanzen

LenalidomideReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, stuqingzhang@126.com.
  • Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.

Zitieren

APA

Zhang, Q., Dong, Y., Zhai, Z., Tao, L., & Tao, Q. (2024). Lenalidomide Treatment of Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy. Acta Haematologica. https://doi.org/10.1159/000537719

Vancouver

Zhang Q, Dong Y, Zhai Z, Tao L, Tao Q. Lenalidomide Treatment of Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy. Acta Haematologica. 2024. doi:10.1159/000537719

BibTeX
@article{Zhang2024,
  author = {Zhang, Qing and Dong, Yi and Zhai, Zhimin and Tao, Lili and Tao, Qianshan},
  title = {Lenalidomide Treatment of Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000537719}
}
Kostenlos starten →